We are focused on making a difference for patients with Eosinophilic Esophagitis

Our Company

Ellodi Pharmaceuticals is a gastroenterology-focused specialty pharmaceutical company aiming to advance treatments for Eosinophilic Esophagitis (EoE), a rare and chronic allergic inflammatory condition. The company was established in 2020 to accelerate clinical development of EoE therapies, particularly APT-1011, which is currently in clinical development. Despite growing awareness of EoE and its underserved patient population, no FDA approved oral treatment exists today for first-line use.

Ellodi Pharmaceuticals has assembled a seasoned team with deep expertise in developing and commercializing innovative therapies for gastrointestinal disorders and rare diseases. With patients and caregivers at the center of every decision we make, we are focused on developing and delivering innovative therapies that can meaningfully improve and transform the lives of patients with EoE.

Troy Hamilton

CEO

Troy Hamilton has more than 26 years of experience in the pharmaceutical, biotechnology, and healthcare industries. Previously, he held several executive and global commercial leadership roles at Adare Pharmaceuticals, Synergy Pharmaceuticals, Shire Pharmaceuticals, and Johnson & Johnson. Troy has significant Gastroenterology-related experience in functional gastrointestinal disorders, inflammatory bowel disease, eosinophilic esophagitis, short bowel syndrome, rare pediatric cholestasis, and acid-peptic disorders. He also serves as a board member at Lazarus Pharmaceuticals, metaMe Health, and Bethanamist and board advisor at New Perspectives. Troy received his Bachelor of Science, Doctorate, and MBA degrees from Saint Joseph’s University (Philadelphia College of Pharmacy and Haub School of Business).

 

Troy Hamilton

CEO

Troy Hamilton has more than 26 years of experience in the pharmaceutical, biotechnology, and healthcare industries. Previously, he held several executive and global commercial leadership roles at Adare Pharmaceuticals, Synergy Pharmaceuticals, Shire Pharmaceuticals, and Johnson & Johnson. Troy has significant Gastroenterology-related experience in functional gastrointestinal disorders, inflammatory bowel disease, eosinophilic esophagitis, short bowel syndrome, rare pediatric cholestasis, and acid-peptic disorders. He also serves as a board member at Lazarus Pharmaceuticals, metaMe Health, and Bethanamist and board advisor at New Perspectives. Troy received his Bachelor of Science, Doctorate, and MBA degrees from Saint Joseph’s University (Philadelphia College of Pharmacy and Haub School of Business).